公开(公告)号：US20220257631A1

公开(公告)日：2022-08-18

申请号：US17595587

申请日：2020-05-20

Applicant: BIONTECH SE ,  TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ

Inventor： Ugur SAHIN ,  David WEBER ,  Carina WALTER ,  Diana BAREA ROLDAN ,  Ruprecht KUNER ,  Meike WAGNER ,  Martin SUCHAN ,  Stefania GANGI MAURICI ,  Stefanie HUBICH-RAU ,  René BECKER

IPC: A61K31/7088 ,  A61P35/00 ,  A61K9/00

Abstract: Disclosed herein are compositions, uses, and methods for treatment of ovarian cancers. In one aspect, provided herein is a composition or medical preparation comprising at least one RNA, wherein the at least one RNA encodes the following amino acid sequences: (i) an amino acid sequence comprising claudin 6 (CLDN6), an immunogenic variant thereof, or an immunogenic fragment of the CLDN6 or the immunogenic variant thereof; (ii) an amino acid sequence comprising p53, an immunogenic variant thereof, or an immunogenic fragment of the p53 or the immunogenic variant thereof; and (iii) an amino acid sequence comprising Preferentially Expressed Antigen In Melanoma (PRAME), an immunogenic variant thereof, or an immunogenic fragment of the PRAME or the immunogenic variant thereof.

公开(公告)号：US20220143144A1

公开(公告)日：2022-05-12

申请号：US17442568

申请日：2020-04-02

Applicant: BIONTECH SE ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Inventor： Ugur SAHIN ,  Mathias VORMEHR ,  Lena KRANZ ,  Sina FELLERMEIER-KOPF ,  Alexander MUIK ,  Daniel REIDENBACH ,  Mustafa DIKEN ,  Sebastian KREITER

IPC: A61K38/20 ,  A61K38/21 ,  A61P37/04 ,  A61P35/00

Abstract: The present disclosure relates to methods and agents for enhancing the effect of immune effector cells, in particular immune effector cells that respond to interleukin-2 (IL2), for example effector T cells such as CD8+ T cells. Specifically, the present disclosure relates to methods comprising administering to a subject a polypeptide comprising IL2 or a functional variant thereof or a polynucleotide encoding a polypeptide comprising IL2 or a functional variant thereof and a polypeptide comprising type I interferon (IFN) or a functional variant thereof or a polynucleotide encoding a polypeptide comprising type I interferon or a functional variant thereof.

公开(公告)号：US20250009780A1

公开(公告)日：2025-01-09

申请号：US18578844

申请日：2022-07-13

Applicant: BIONTECH SE

Inventor： Ugur SAHIN ,  Christiane STADLER ,  Claudia LINDEMANN ,  Ursula ELLINGHAUS ,  Hayat BÄHR-MAHMUD ,  Leyla FISCHER ,  Anuhar CHATURVEDI ,  Gábor BOROS ,  Jonas REINHOLZ ,  Sergey BESSONOV ,  Katalin KARIKÓ

IPC: A61K31/7115 ,  A61K9/00 ,  A61K9/127 ,  A61K9/51 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

Abstract: The present invention generally relates to binding agents that are at least bispecific for the binding to CD3 and CLDN6, i.e., they are capable of binding to at least CD3 and CLDN6. Specifically, the present invention relates to RNA encoding these binding agents which may be used in the treatment or prevention of cancer in a subject.

公开(公告)号：US20230399403A1

公开(公告)日：2023-12-14

申请号：US18035172

申请日：2021-11-11

Applicant: BioNTech SE

Inventor： Ugur SAHIN ,  Karsten BECKMANN ,  Claudia PAULMANN ,  Sina FELLERMEIER-KOPF ,  Friederike GIESEKE ,  Alexander MUIK ,  Ivan KUZMANOV

IPC: C07K16/28 ,  G01N33/574

CPC classification number: C07K16/2818 ,  G01N33/57492 ,  C07K2317/565 ,  G01N2333/70521 ,  C07K2317/92 ,  C07K2317/76 ,  C07K2317/24

Abstract: The present disclosure relates to antibodies having the ability of binding to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody having the ability of binding to the immune checkpoint protein PD-1, such as human PD-1, or a nucleic acid encoding such an antibody, or a composition comprising said antibody or nucleic acid.